Abstract Synthetic beta-tricalcium phosphate ceramic (Biosorb, S.B.M., Lourdes, France) was used as a bone substitute in 110 patients whose mean age was 48 (14-83) years. There was a wide spectrum of indications, and the material was used alone in 86, combined with a corticocancellous bone autograft in 22, and combined with a corticocancellous allograft in two. The patients were assessed clinically and radiographically. Incorporation of the ceramic was excellent in 30, good in 51, and fair in 26. There were no poor results. In three patients the implanted material was removed because of infection. Incorporation was good or excellent in about 75% of all 110 patients. We consider beta-tricalcium phosphate ceramic to be the substitute of choice for mediumsized bone defects.
Introduction
During the past 10 years there has been a greatly increased use of bone graft substitutes [20, 30] . One of these, calcium phosphate ceramic has been particularly successful [33, 34] This material was originally developed for use in dentistry and maxillofacial surgery but is now also being used in orthopaedic surgery [4, 14, 31, 44] . Bone graft substitutes are a useful alternative to biological materials such as autografts, allografts and xenografts, and to natural materials such as coral. Many in vitro and in vivo studies [5, 23, 32, 36] have shown that calcium phosphate ceramics are fully biocompatible and the physical and chemical properties of these substances make them bioactive [11, 32, 36] . In addition, calcium phosphate ceramics are osteoconductive and resorbable [10, 28] , i.e. they provide a scaffolding for new bone formation [22] , and their macroporosity allows bone and cells to grow into the ceramic [6, 13, 40] . Although calcium phosphate ceramics, including tricalcium phosphate, have been extensively investigated in animal studies [8, 7, 21, 22, 24, 25, 26, 27, 29, 37, 41] , there are only a few studies describing the use of these bone graft substitutes in orthopaedics and traumatology [4, 14, 16, 19, 31, 35] . We report a retrospective study of 110 patients in whom beta-tricalcium phosphate ceramic was used in bone surgery.
Materials and methods
The implants used in this study were made of synthetic beta-tricalcium phosphate ceramic (Ca 3 (PO 4 ) 2 ) (Biosorb; S.B.M., Lourdes, France). This material is macroporous with a total pore volume of 45%±5% and a pore size between 250 and 400 µm. It is fully biocompatible and bioactive, and its synthetic origin ensures that there are neither problems of immune intolerance nor any risk of viral transmission. It is also osteoconductive and resorbable and has a compressive strength of 15 MPa. In this study 1.5 mm-diameter granules or blocks of various sizes were used to fill the defect. The material was used on one occasion in each of 110 patients, of whom 56 were men and 54 were women. Their age range was from 14 to 83 years with a mean of 48 years.
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The operations were performed between January 1993 and December 2000, and the patients were reviewed after a minimum of 6 months. The material was used for a wide variety of reasons. There were nine cases of aseptic non-union of a limb bone and one delayed union of the humerus. Fourteen patients had a benign tumour or a tumour-like lesion (Fig. 1a-e ). There were four cases of osteonecrosis and five of osteochondritis, and 35 patients had suffered an injury. Arthrodesis was performed in 23 patients, the majority being in the foot and ankle. There were ten revisions of total hip prostheses that had developed aseptic loosening. Six of the operations were performed for an assortment of indications.
Defects were classified using the GESTO system [15] produced by the French Association for the Study of Grafts and Tissue Substitutes in Orthopaedics (Association pour l'Étude des Greffes et Susbstituts Tissulaires en Orthopédie). Defects are described and graded in terms of three features: (1) type (type of defect: grade 0=bone graft substitute used as an onlay graft, grade I=loss of substance but bone continuity preserved, grade II=loss of continuity with preservation of some contact with bone or bone marrow, grade III=no continuity or contact with bone or bone marrow); (2) osseous structure (type of bone surrounding the defect and thus in contact with the implant: cortical bone, cancellous -union  2  20  8  80  0  0  0  0  0  0  Malunion correction  0  0  3  100  0  0  0  0  0  0  Benign tumour  5  34  7  50  2  14  0  0  0  0  Osteonecrosis  1  25  1  25  2  50  0  0  0  0  Osteochondritis  1  20  4  80  0  0  0  0  0  0  Trauma  11  32  15  43  6  17  0  0  3  9  Arthrodesis  5  22  9  40  9  40  0  0  0  0  Total hip arthroplasty revision  2  20  2  20  6  60  0  0  0  0   113 bone, or corticocancellous bone; and (3) dimension (greatest distance between a point in the implanted material and the surrounding host bone: D-=distance less than 10 mm, D+=distance equal to or greater than 10 mm). The defect to be filled was located in cancellous bone in 55 patients (50%), in cortical bone in 23 (21%), and in corticocancellous bone in 32 (30%). In the majority of patients the bone graft substitute was used in "block form". The material was used alone in 86 patients while in 22 it was combined with a corticocancellous autograft. A femoral head allograft was used in the repair of the acetabulum in two revision arthroplasties. Clinical and radiological assessment was made at review. The radiographic analysis measured three main criteria: the interface between host bone and biomaterial, the radiological density of the biomaterial, and any evidence of biomaterial fracture or fragmentation. A qualitative scale was used in all patients to describe the radiographic patterns observed: poor=no integration of the ceramic by the host bone, fair=limited graft resorption at the periphery, good=substantial but incomplete resorption of the implanted material, and excellent= complete integration. In one patient a biopsy was obtained at the time of removal of the internal fixation "hardware" that had been used to stabilise the graft.
The results, including patient demographic details, diagnoses, and information on lesions (sites, surrounding bone stock, size, adjunctive use of autografts), have been recorded in the "results tables".
Results
Factors assessed were the indication for using the material, the nature of the host site bone stock, and the time since implantation. The results are shown in Table 1 . There was neither implant fragmentation nor migration and no poor results in any of the groups. However, there were three infections among the trauma cases, two of which were associated with tibial plateau fractures and one with a femoral fracture after total knee replacement. Table 2 shows a summary of the results related to the indication for and the quality of the incorporation. The best results were obtained in non-union/delayed union (100% excellent or good integration), malunion (100%), and osteochondritis (100%). These were followed by use for benign tumours (86%), trauma (74%), arthrodesis (61%), osteonecrosis (50%), and hip arthroplasty revision (40%). None of the sites (cortical, cancellous, or corticocancellous) had a poor result. In fact, more cortical than cancellous sites showed excellent incorporation, with corticocancellous sites giving the poorest results (52, 26, and 13.3% respectively). In addition, an excellent quality of integration was obtained in a shorter period of time with implantation in cortical rather than in cancellous sites (16 and 32 months respectively). The mean time to complete resorption of the implant was 22 (21-24) months. One biopsy was taken in a patient when the internal fixation hardware was removed at 16 months after an arthrodesis of the foot, and this revealed ingrowth of lamellar bone into the bone graft substitute.
Discussion
While animal studies of calcium phosphate ceramics have been the subject of many papers over the past 20 years, rather less has been published on the clinical applications of these materials in orthopaedics and traumatology. Several clinical studies have shown interesting results. Cazeau et al. [4] reported good clinical results in a 2-year study of the use of tricalcium phosphate wedges in the repair of tibial plateau fractures. Radiography showed implant incorporation in the second year with no evidence of implant migration. Gouin et al. [16] used either blocks or granules of a macroporous biphasic ceramic (60% hydroxyapatite, 40% beta-tricalcium phosphate) in 23 patients. The indications were benign tumours, non-union, osteotomy, and defect filling after excision of malignant tumours of the pelvis. The mean follow-up was 20 months, and no harmful local or regional effects attributable to the ceramic were seen. Union was achieved in all patients. Three biopsies were performed at the time of removal of internal fixation, and lamellar bone was found in the pores. Lantuejoul et al. [31] reported a series of 55 patients managed with tricalcium phosphate bone graft substitutes and followed for a mean of 18 months. Resorption of two-thirds of the substitute was noted at the last review. These implants were used in patients with non-traumatic orthopaedic problems (bone tumours, arthrodesis, non-union, tibial openingwedge osteotomy), and the results were very satisfactory. Giannini et al. [14] and Zheng et al. [44] also reported good results with calcium phosphate ceramics used in orthopaedics. Passuti et al. were sufficiently encouraged by their experience with macroporous biphasic (hydroxyapatite/tricalcium phosphate) ceramics in interbody fusion in dogs [8] to use this material in humans [35] . Twelve patients with severe scoliosis (neuromuscular scoliosis, osteogenesis imperfecta) and insufficient bone for autografting underwent vertebral fusion using biphasic ceramic blocks with or without associated autografts. At 15 months there was neither any clinical nor radiographic differences between the ceramic-plus-autograft and the ceramic-only groups, and two fusion-site biopsies showed excellent integration of the ceramic.
Our study, in which only beta-tricalcium phosphate was used, confirms the beneficial effects reported by other authors. The rate of satisfactory (excellent and good) results was 74%, with no poor results in any of the 110 patients. The excellent results in non-union/delayed union may appear surprising given that these sites are inherently non-conducive to osteogenesis. However, the freshening of the bone ends and the restoration of the medullary canal associated with the procedure appear to have improved the local environment. Our results in benign tumours are in line with those reported by such authors as Gouin [16] and Lantuejoul [31] . Arthrodesis proved to be a good indication for the use of ceramic plus autografts, especially in the foot and the ankle, while osteonecrosis with only 50% of fair results did less well -although there was no fibrous encapsulation in either category. This was no doubt attributable to the poorly vascularised (necrotic) host bone. The mean time to integration of 22 (21) (22) (23) (24) months found in our study was calculated without any account being taken of osteonecrosis, osteochondritis, malunion, or hip revision surgery. Exchange arthroplasty had the highest rate of fair results (60%), with excellent results in only 20% of cases.
Implantation in cortical bone did not appear to affect the quality or speed of ceramic integration. It was interesting that the time from implantation for excellent integration to be attained was shorter at the cortical than at the cancellous sites. This observation, and the fact that in some patients incorporation was seen to be only fair at a mean of 12 months from implantation while in others good integration had been achieved by a mean of 11 months, suggests that time is not the only factor affecting implant integration. Such factors as implant size and volume, bone stock quality, and patient age need to be taken into account. As expected, we also found that bone graft substitutes were better osseointegrated where the defects were small. This observation was made in benign tumours, non-union or delayed union, and arthrodesis, as well as in some of the trauma cases. We therefore agree with Frayssinet and Autefage [12] that large defects do not lend themselves to the use of ceramic fillers, the probable reason being a lack of osteogenic cells at the host site. Implantation in weightbearing zones does not appear to be a problem, providing that the area is sufficiently reinforced with internal fixation. It is interesting to note that Trécant et al. [39] using a biphasic ceramic found that, following implantation, there was a significant increase in the compressive strength of the "composite" formed by the transformed ceramic and the newly formed bone. Bouler et al. [3] found the mechanical strength of biphasic ceramics to be affected by macroporosity (which decreases the compressive strength) and the sintering temperature (which increases the compressive strength).
While no fibrous encapsulation was encountered in our study, three of our 110 patients (3%) developed infections requiring implant removal. Infection occurred only in trauma cases and especially in tibial plateau fractures. This compares favourably with the infection rate of 22% reported by Hardy et al. [17] following the use of a porous hydroxyapatite ceramic. Why infections should occur is not fully understood, and further studies are needed to show what causes these problems and how to prevent them. One interesting suggestion is to use the bone graft substitute as an antibiotic delivery system [38] in order to produce higher and more prolonged (>12 h) levels than is possible with systemic administration. The clinical utility and practical aspects of this technique require further investigation.
Like all studies of calcium phosphate bone graft substitutes in human subjects, the evidence we assessed was almost exclusively radiographic. Histological investigations are invasive so they cannot be repeated at will. Therefore they are rarely undertaken. Such studies as have been reported [15, 16, 35] have confirmed the results of animal studies [8] by showing that calcium phosphate ceramics are well integrated. Our own observation from the one biopsy taken during this study also showed ingrowth of lamellar bone. In our radiographic analysis three criteria were used to obtain the fullest possible evidence, and we consider these criteria to be reasonably reliable indicators of bone resorption and ingrowth. The same criteria were used by Uchida et al. [41] , who studied a hydroxyapatite ceramic, and by Gouin et al. [16] , who used a macroporous biphasic ceramic. Our findings of the essential blending of the radiographic pattern of bone and bone substitute and the absence of a peripheral lucency support the findings of Uchida et al. [42] .
In conclusion, beta-tricalcium phosphate ceramic is a valuable addition to the surgeon's armamentarium, especially for the filling of medium-sized defects in benign tumour and limb trauma cases. In arthrodesis and nonunion we do not routinely employ this material, but on occasion we will use it to complement and augment an autograft. It is hoped that the current restriction of its use to the filling of smaller defects will be overcome by the development of cell cultures [1, 2, 5] and of osteoinductive factors [9, 18, 34, 43] designed to endow the ceramics with osteogenicity and osteoinductivity. More experimental work and clinical studies will be required in order to resolve these problems.
